ERBB2 and breast carcinoma: Neratinib (tyrosine kinase inhibitor) inhibited the action of proteins by binding with adenosine triphosphate (ATP), leading to the inhibition of phosphorylation on EGFR, HER2, HER3, HER4, AKT and ERK inSKBR3 and BT474 cells (HER2+ breast cancer cells).